07-11-2012

Keryx Biopharmaceuticals, Inc. announced the initiation of a Phase 2 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney ...

more

18-10-2011

A new spin-off company from the National University of Singapore (NUS), called Nephron Dx, has recently been set up to develop a more accurate diagnostic kit for the earlier detection of diabetic chronic kidney disease. Nephron Dx aims to enter the multi-billion dollar kidney disease ...

more

Blood test could identify patients who need treatment

13-09-2011

The blood levels of a particular hormone can help predict which kidney disease patients will develop heart problems, need dialysis, and die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). Testing for this hormone could ...

more

Pivotal clinical trial will further assess drug candidate's effect on kidney function

20-06-2011

Reata Pharmaceuticals, Inc. and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes.The trial, known as BEACON (Bardoxolone ...

more

03-05-2011

Keryx Biopharmaceuticals, Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) for the development of Zerenex™ (ferric citrate) for the management and control of serum phosphorus in end-stage renal disease (ESRD) patients undergoing dialysis, ...

more

26-01-2011

Hybrigenics (ALHYG) announced it has received from the European Patent Office the official notification of its intent to grant Hybrigenics’ patent on therapeutic uses of high doses of inecalcitol, under an accelerated procedure. Originally filed in 2009, this patent will cover inecalcitol ...

more

23-11-2010

Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease). Study results ...

more

Results Suggest Bardoxolone Methyl May Reduce the Stage of Disease and Improve Measures of Kidney Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

22-11-2010

Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney ...

more

27-09-2010

Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). Under terms of the agreement, Reata ...

more

Widening its clinical application to hormone-dependent prostate cancer, hyperparathyroidism, and severe psoriasis

21-09-2010

Hybrigenics announced the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients. The maximal tolerated dose of inecalcitol is 4 milligrams (mg) per day and the ...

more